08.09.2010

Merck Sees Fast Ruling in Johnson and Johnson's Remicade Arbitration

Merck said an arbitration panel would look in late September at whether the company is entitled to overseas rights to Remicade and Simponi, Johnson & Johnson's important rheumatoid arthritis drugs. Merck has said it acquired those rights to the drugs with its $41 billion purchase of Schering-Plough Corp last November. In a regulatory filing, Merck said the arbitration involving blockbuster arthritis treatment Remicade and a potentially lucrative newer drug called Simponi would take place in New York and probably last no more than 12 business days. more